QMS: Whack-a-mole: When QMS workloads outgrow the team, “closure sprints” and shiny eQMS tools create the illusion of control, but only root causes and meaningful KPIs stop the cycle.
QMS: 30-Day Deployment: A structured set of weekly sprints builds the phase-appropriate QMS foundations sponsors need for clinical submissions, fast, bespoke, and workable, with committed client engagement.
Leadership
Interim Leadership: When a leader exits and the room wobbles, interim leadership steadies people, re-aligns delivery, and keeps leadership updates visible and defensible until a clean handover.
Diligence
Due Diligence: The Deal Isn’t the Deck: In fast pharma deals, value sits in technical reality, systems, facilities and people, so diligence must surface red flags and options early enough to change the deal or the first 90-day plan.
Aseptic Assurance
Aseptic Failures: Don’t Blame the Operator: Aseptic failures rarely start with operators, so a proper aseptic assessment follows controls from dock to dock, challenges “Grade A is bulletproof,” and leaves a roadmap the site can run.
Artificial Intelligence
AI Deployment: If You Can’t Explain It, You Can’t Keep It: AI and ML only create value in regulated pharma when intended use, governance, validation, monitoring, and human accountability are clear and defendable.
Vendor Assurance
Vendor Assurance: The CDMO (Supplier) Isn’t the Risk. The Interface Is: Vendor assurance is an operating model across suppliers, where clear boundaries, escalation, and tiered oversight prevent supply shocks becoming programme failures.
Company and System Integration
Integration: Where Good Plans Go to Die: Integrations fail at interfaces, data equivalence, ownership gaps, and culture drift, so an Integration Master Plan must manage boundaries to protect supply and compliance.
Inspections
Inspection Readiness: The Inspector Is Not the Problem: Inspection outcomes are decided by everyday habits, evidence quality, and human performance under pressure, so readiness means “how we work normally,” not a pre-inspection sprint.
GDP and Supply Chain
Cold Chain: Hot Consequence: A practical guide to autologous vein-to-vein cold chain control, showing how to select and govern logistics vendors and build defensible Chain of Identity and Chain of Custody so shipments do not fail at the handover.
Clinical Trials
CTA & IND: The Submission Is Not the Science: A practical playbook for building US INDs and converting them into EU CTAs and IMPDs through CTIS, aligning CTD content, CMC readiness, sponsor oversight, timelines, and regulator engagement to protect trial start dates.